Ulrike Tontsch-Grunt

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases

R. Doebele, A. Le, T. Voss, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

Łukasz M. Boryń, J. Zuber, A. Stark, 2015, Nature.

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

W. Sommergruber, F. Hilberg, Ulrike Tontsch-Grunt, 2008, Cancer research.

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).

F. Hilberg, Ulrike Tontsch-Grunt, F. Colbatzky, 2009, Journal of medicinal chemistry.

Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.

I. Waizenegger, Daniel Gerlach, N. Kraut, 2018, Cancer letters.